Health Economics›Transformed lymphoma›All lines of therapy

All lines of therapy

Transformed lymphoma · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~13.2 mo	—	~29	~R 8 321 703 PFS proxy · indirect	1
Glofitamab monotherapy Variant #01	—	R 219 579	21d	—	—	—	—	—
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	—	~8.5 mo	—	—	1
OFAR Variant #01	—	R 31 743	28d	—	—	—	—	—
R-DHAP Variant #06	—	R 17 673	21d	—	~31.1 mo	—	—	2
R-GDP Variant #01	—	R 15 361	21d	—	~31.1 mo	—	—	1
R-EPOCH Variant #01	—	R 13 350	21d	—	—	—	—	—
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~8.7 mo	—	~3	~R 19 084 PFS proxy · indirect	3
Lenalidomide and Tafasitamab Variant #01 Partial	—	R 5 445	28d	—	—	—	—	—
Bendamustine monotherapy Variant #01	—	R 5 419	—	~16.5 mo	—	—	—	2
Epcoritamab monotherapy N/A - secondary systemic drug	—	R 169	—	—	—	—	—	—
Loncastuximab tesirine monotherapy N/A - secondary systemic drug	—	R 139	21d	—	—	—	—	—
Axicabtagene ciloleucel monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	1
131Iodine-Tositumomab monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	—
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Selinexor monotherapy Variant #01 Partial	—	—	7d	~2.8 mo	—	~13	—	1

17 of 17 regimens shown